Biosimilar insulin substitution sparks safety concerns
A federal law that allows pharmacists to substitute biosimilars without input from a clinician has been criticised by Diabetes Australia.
The organisation says subtle differences between biosimilar insulin and insulin could reduce the effectiveness of treatment.
The proposed changes could mean the insulin may be switched at pharmacy level without knowledge of diabetes healthcare teams, it says.
“In addition to an alternate insulin, patients could be supplied with different devices which they are not trained to use.”
Changing the dosage